As consumers taking medications like Ozempic cut back on eating out, about 70% are spending more on cooking at home, ...

Coca-Cola (NYSE:KO) is not seeing the huge effect from GLP-1 usage that some investors feared when the drugs became more ...

Four clinical organizations jointly release an advisory with evidence-based nutrition and lifestyle interventions to enhance ...

Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use new ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

IFF is in the early stages of exploring GLP-1 consumer segmentation to help brands move beyond a one-size-fits-all approach toward one grounded in empathy, specificity and long-term relevance. The ...

Although coverage restrictions remain in place, the trendiness of weight loss drugs may be creating a growing cost concern ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.

Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs. Eli Lilly (NYSE: LLY) has been a ...